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OBJECTIVE: Schizophrenia is associated with increased morbid-
ity and mortality compared to the general population, largely
resulting from increased incidence of cardiovascular disease
and diabetes. Some atypical antipsychotics are associated with
adverse metabolic symptoms, such as weight gain, dyslipidaemia
and glucose dysregulation, which may further increase the risk of
coronary heart disease (CHD) and diabetes. This study aimed to
assess the impact of these symptoms on cost of treating patients’
physical health. METHODS: Data from the Schizophrenia Trial
for Aripiprazole (STAR) study showed that metabolic side effects
of aripiprazole treatment are less than those experienced by
patients receiving standard-of-care (SOC) treatment (physicians’
selection of olanzapine/quetiapine/risperidone). In a post-hoc
analysis, projected risks for diabetes/coronary heart disease
(CHD) were calculated using the Stern and Framingham models.
These risks were used to estimate the difference in direct and
indirect cost consequences of diabetes and CHD in schizophrenia
patients treated with aripiprazole or SOC over a 10-year period,
assuming risk of diabetes onset/CHD events remained linear.
Diabetes costs were estimated from UKPDS and UK T2ARDIS
studies, respectively, and CHD costs were estimated using preva-
lence data from the Health Survey of England and published
literature. All costs were inﬂated to 2007 costs using the UK
government’s Pay and Prices Index inﬂation rates. RESULTS:
The number of avoided diabetes cases (23.4 cases/1000 treated
patients) in patients treated with aripiprazole compared with
SOC was associated with estimated total (direct and indirect)
cost savings of 37,261,293 over ten years for the UK popula-
tion. Similarly, the number of avoided CHD events (3.9 events/
1000 treated patients) was associated with estimated total cost
savings of 7,506,770 over ten years. CONCLUSION: Com-
pared with SOC, the favourable metabolic proﬁle of aripiprazole
treatment may provide reductions in health and economic
burden to schizophrenia patients and psychiatric health care
services in the UK.
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OBJECTIVE: To review the economic burden of Generalized
Anxiety Disorder (GAD) by examining published North Ameri-
can studies and to use this information to deﬁne burden and cost
of illness among patients with GAD. METHODS: A systematic
review of the literature was conducted using a PICO (Population,
Intervention, Comparison, Outcomes) form to guide the search
strategy. MEDLINE, EMBASE, and Cochrane Library databases,
and selected websites, were examined. The search was limited to
papers published in English between 1987 and 2007. Studies
examining outcomes from mixed patient populations, com-
bination therapies or non-pharmacological interventions were
excluded. RESULTS: The initial search yielded a total of 1999
articles, of which approximately 100 met predetermined inclu-
sion criteria. The studies revealed 12-month prevalence rates
ranging from 1.6–3.0%. GAD prevalence was higher among
females compared with males and generally decreased with age.
Comorbid mental disorders were common among patients with
GAD, particularly depressive disorders, and were highly predic-
tive of GAD onset and persistence. GAD was also associated with
a substantive reduction in health-related quality of life. SF-36
scores in one study were 12–28 points lower among patients with
GAD compared with the general US population (1). The health
care resource utilization costs associated with GAD were consid-
erable, although varying patterns of disease identiﬁcation and
treatment made the extent of this utilization difﬁcult to quantify.
Patients with GAD showed signiﬁcantly higher medical care
charges ($2375 vs. $1448, P = 0.006) than patients without
GAD (2). CONCLUSION: GAD, along with other anxiety dis-
orders, exerts substantial cost-related burdens on society, driven
in part by under-recognition and under-treatment of the disorder.
Increased awareness, evidence-based treatment selection and
appropriate early intervention could help to alleviate this burden.
PMH39
THE PREVALENCE AND COSTS OF METABOLIC CONDITIONS
AMONG PATIENTSWITH BIPOLAR DISORDERS AS
COMPAREDTO MATCHED CONTROLS
Mark TL1, Centorrino F2,Talamo A2, Oh K1, Chang J3
1Thomson Healthcare,Washington, DC, USA, 2Harvard Medical
School/McLean Hospital, Belmont, MA, USA, 3Bayer HealthCare
Pharmaceuticals, Pine Brook, NJ, USA
OBJECTIVE: Patients with bipolar disorder are vulnerable to
developing metabolic illnesses such as hypertension, dyslipi-
demia, and type 2 diabetes mellitus. In addition, mood stabiliz-
ers, anticonvulsants, and antipsychotic medications, which are
commonly used to treat bipolar disorder, have been linked to risk
for adverse metabolic changes. This study uses a large insurance
claims database to examine the prevalence and costs of metabolic
conditions among patients with a bipolar diagnosis relative to
a matched non-bipolar sample. METHODS: A retrospective
analysis was conducted of medical service and prescription
claims from the Thomson Health care MarketScan® Commer-
cial Database (includes claims information on more than 12
million employees with employer-based insurance and their
dependents in the United States). Claims data for 28,531 patients
with bipolar disorder were compared over one year with data for
85,593 age and gender 1–3: matched control patients with no
mental health disorders and no psychotropic medication use. The
prevalence and health care costs of metabolic conditions in
bipolar patients were compared with those of their matched
controls. RESULTS: The bipolar cohort had signiﬁcantly higher
overall medical service and prescription drug costs than the
control cohort ($12,764 versus $3,140, p < 0.0001). Bipolar
patients had a signiﬁcantly higher prevalence of metabolic
co-morbidities than the general population (37% versus 30%,
p < 0.0001), and medical service treatment costs for metabolic
conditions were twice that of the control cohort ($531 versus
$233, p < 0.0001). Prescription medication costs for metabolic
conditions were higher as well, with bipolar cohort per-patient
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